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Background. More than 5% of the United States population
has been diagnosed with nephrolithiasis and about one half of
(first-time) stone formers will have a recurrence within 5 years.
The prevalence of nephrolithiasis is concentrated among work-
ing age adults, yet little prior work has examined the economic
burden of the disease on employers and their employees. We
sought to estimate the direct and indirect costs of nephrolithi-
asis for working age adults (18–64) with employer-provided
insurance.
Methods. This was an observational study using retrospec-
tive claims data. Detailed medical and pharmacy claims from
25 large employers and absentee data from a subset of firms
were used to estimate the direct and indirect costs associated
with nephrolithiasis in a privately insured, nonelderly popula-
tion. Multivariate regression models were used to predict health
care expenditures for persons with and without the condition,
controlling for differences in patient (health status) and plan
characteristics.
Results. More than 1% of working-age adults were treated
for nephrolithiasis in 2000. Prevalence was considerably higher
among men and employees age 55 to 64. About one third of
employees treated for nephrolithiasis in 2000 missed work due
to the condition, with an average work loss for the entire treated
population of 19 hours per person. Conditional on receiving
treatment, the incremental costs of nephrolithiasis were $3,494
per person in 2000.
Conclusion. The direct and indirect costs of nephrolithiaisis
are substantial among working-age adults. Interventions that
prevent recurrence among known stone formers may be a cost-
effective component of disease management programs.
Most chronic conditions such as hypertension, coro-
nary artery disease, type II diabetes, and chronic obstruc-
tive pulmonary disease (COPD) affect late middle-aged
and older adults. As such, the economic burden associ-
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ated with these conditions is largely borne by the Medi-
care program. While nephrolithiasis is far less prevalent
in the general population, it is a chronic condition that
primarily affects working-age adults [1]. The incidence
of nephrolithiasis peaks between the ages of 20 and 60
and 50% of stone formers will have a recurrence within
5 years [2]. Further, recent evidence suggests the preva-
lence of nephrolithiasis is increasing rapidly [3]. Data
from the National Health and Nutrition Examination
Survey (NHANES III, 1998–1994) indicate that over 5%
of the United States population has been diagnosed with
nephrolithiasis in their lifetime, a 77% increase from the
prior survey (NHANES II, 1976–1980) [4]. While the dis-
ease is more common in men, prevalence is increasing at
a faster rate among women [5].
The rising prevalence of nephrolithiasis and the mor-
bidity associated with it suggest that the economic costs of
the disease are substantial. Treatment of nephrolithiasis
depends on stone size and location, but typically involves
a surgical procedure such as extracorporeal shock wave
lithotripsy (ESWL), ureteroscopic laser lithotripsy, or
percutaneous nephrostolithotomy (PCNL). These proce-
dures require an inpatient or outpatient surgical visit, and
postsurgical care. Stones treated conservatively, in expec-
tation of spontaneous passage, can often result in visits
to the emergency room for pain control or treatment of
nausea and vomiting.
Dietary modifications, including increasing water in-
take, restricting dietary sodium, and reducing excessive
meat consumption can reduce the risk of stone formation
[6]. For individuals with specific metabolic abnormalities,
medical therapies such as thiazide diuretics and urinary
alkalinizing agents can reduce the risk of a second kidney
stone [6]. A meta-analysis of 12 randomized controlled
prevention trials revealed that prescribing oral medical
therapy after a first stone significantly reduced the risk of
new stone formation [7].
The rapid adoption of disease management programs
over the past 5 years by United States firms has focused
almost exclusively on a small number of highly prevalent
conditions such as diabetes, asthma, and heart disease.
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Yet many less prevalent conditions, such as nephrolithia-
sis, primarily affect working-age adults and have been
shown to respond to secondary prevention programs.
Quantifying the full economic burden of the disease can
help employers determine whether nephrolithiasis is a
worthy target for existing disease management programs.
METHODS
Case definition
Administrative codes used to identify individuals with
nephrolithiasis and procedures used to treat nephrolithi-
asis are listed in Table 1.
Data sources
We used two data sources to examine the direct and in-
direct costs associated with nephrolithiasis in a privately
insured, nonelderly adult population (ages 18–64). Data
on medical and pharmaceutical use were obtained from
Ingenix, Inc. (Salt Lake City, UT, USA), a health ben-
efits consulting firm. Data on work loss associated with
the treatment of nephrolithiasis were based on the Med-
stat Marketscan Health and Productivity Management
Database (Marketscan, Ann Arbor, MI, USA).
Direct costs
We used a data set of medical and pharmacy claims of
25 large United States employers covering 322,556 ben-
eficiaries age 18 to 64 who were continuously enrolled
for the entire 2000 calendar year. We excluded depen-
dents and employees age 65 and older because we could
not be sure their medical and pharmacy utilization was
not covered by other insurance. Claims files captured all
health care claims and encounters, including prescription
drugs, inpatient, emergency, and ambulatory services.
The medical claims included date of service, diagnosis and
procedure codes, types of facility, and providers, and ex-
penditures, including billed charges, negotiated discounts,
excluded expenses, deductibles, copayments and pay-
ments made by the employer, employee, and other third-
party coverage. Drug claims included information on the
type of drug (drug name, national drug codes, dosage,
supply), place of purchase (retail or mail order), and ex-
penditures.
Claims data contain records only for those who used
services. To identify those who may not have used ser-
vices, enrollment data were also obtained. Enrollment
files included each person’s age, sex, plan type (FFS, PPO,
POS, HMO), zip code of residence, and relationship to
employee. The claims data were linked with information
about plan benefits. Characteristics of the medical bene-
fit included plan deductibles, copayments and/or coinsur-
ance rates for physician office visits and inpatient services,
and plan type. The drug benefit design features we coded
Table 1. International Classification of Diseases, 9th ed., and
common procedural terminology—4 administrative code–based
algorithms used to define cases of nephrolithiaisis
Anyone with
ICD-9 diagnosis code
592.0 Calculus of kidney (excludes uric acid stone)
592.0 Kidney infection with calculus
592.1 Calculus of ureter
592.9 Urinary calculus, unspecified
274.11 Uric acid nephrolithiasis
270.0 Cystinuria
Anyone with the following diagnosis code and any of the following
procedure codes, or the procedure code alone
271.8 Hyperoxaluria
ICD-9 procedure code
55.03 Percutaneous nephrostomy without fragmentation
55.04 Percutaneous fragmentation with fragmentation
55.92 Repeat nephroscopic removal during current episode
56.0 Transurethral removal of obstruction from ureter and renal
pelvis (stone, blood clot, foreign body)
56.2 Ureterotomy for removal of calculus or exploration
59.8 Transurethral manipulation of obstruction from ureter
without removal of obstruction
59.8 Transurethral ureteral stent placement for passage
of calculus
59.95 Ultrasonic fragmentation of urinary stones
98.51 ESWL
CPT code
50060 Nephrolithotomy; removal of calculus
50065 Secondary surgical operation for calculus
50070 Nephrolithotomy complicated by congenital kidney
abnormality
50075 Removal of large staghorn calculus filling renal pelvis
(includes anatrophic pyelolithotomy)
50080 Percutateous nephrostolithotomy with or without
lithotripsy, up to 2 cm
50081 PCNL, over 2 cm
50130 Pyelotomy, with removal of calculus
50590 ESWL
50610 Ureterolithotomy; upper one third of ureter
50620 Ureterolithotomy, middle one third of ureter
50630 Ureterolithotomy, lower one third of ureter
52320 Cysto, ureteral cath, removal of calculus
—52325 With fragmentation of calculus (ultrasound or EHL)
—52330 With manipulation, but not removal of stone
52335 Cysto with ureteroscopy and diagnostic
—52336 With removal of stone
—52337 With lithotripsy
other related CPT codes
50945
50135
50561
50580
51060
51065
50961
50980
included copayments or coinsurance for retail pharma-
cies and whether the plan required generic substitution.
Indirect costs
We used the Marketscan data to estimate lost work
hours associated with the treatment of nephrolithiasis.
The Marketscan data link enrollment files, health care
claims, and absence data for a subset of private employers.
Absence data are derived from employee time-reporting
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Table 1. (Continued.)
Groupings used in analyzing procedure use
Procedure: percutaneous nephrostolithotomy
ICD-9 procedure codes
55.03
55.04
CPT procedure codes
50080
50081
Procedure: open stone surgery
ICD-9 procedure codes
56.2
CPT procedure codes
50060
50070
50075
50125
50610
50620
50630
Procedure: extracorporeal shock wave eithotripsy
ICD-9 procedure code
98.51
CPT procedure code
50590
Procedure: ureteroscopic lithotripsy
ICD-9 procedure code
59.8
56.0
59.95
CPT procedure code
52320
52325
52339
52351
52352
52353
records collected through employer payroll systems and
contain detailed information on when employees were
out of work, the number of work hours missed, and the
reasons for the absences (sickness, short-term disability,
vacation, and other types of leave). The work loss related
to medical treatment for nephrolithiasis is then estimated
by linking reported work absences with the enrollment
file and medical claims. We included only those persons
fully enrolled in the health plan throughout the year and
have an inpatient or outpatient medical claim with a pri-
mary diagnosis for nephrolithiasis. Persons on long-term
disability or Consolidated Omnibus Budget Reconcilia-
tion Act (COBRA) were excluded in our analysis. The
study sample includes 834 employees who were treated
for nephrolithiasis in 2000 and whose absentee data were
available.
Estimating medical spending
Multivariate regression models were used to predict
medical and pharmacy spending in 2000 for persons with
and without a primary diagnosis of nephrolithiaisis in the
medical claims. The primary outcomes of interest were
annual medical and pharmacy expenditures for each per-
son. Expenditures consisted of total annual payments
made by the enrollee (copayments, deductibles, excluded
expenses) and by all third-party payers (primary and sec-
ondary coverage, net of negotiated discounts) for medical
services and outpatient prescription drug claims.
We included a detailed set of covariates to control for
observed differences between individuals with and with-
out a primary diagnosis of nephrolithiaisis. We used the
eligibility file to control for demographic characteristics,
such as age, sex, work status (active or retired), urban
residence, and median household income in the zip code
of residence. The medical claims were used to identify in-
dividuals treated for 34 chronic conditions, such as hyper-
tension, diabetes, congestive heart failure, and asthma. A
binary indicator for each condition was included in the
models. We used the benefits data to control for the gen-
erosity of medical and drug coverage. Plan characteristics
included individual deductibles, copayments and/or coin-
surance rates for medical services and prescription drugs,
and a binary indicator for plan type (HMO, POS, PPO,
FFS).
We used ordinary least squares (OLS) to estimate med-
ical and drug expenditures for each individual in the
sample. The parameter estimates were used to predict
average annual spending for persons with and without
nephrolithiasis, controlling for other factors known to
affect utilization. We chose OLS because it predicted
component expenditures better than generalized linear
models and other two-part estimators.
Estimating work loss
In order to estimate work loss, the dates of an inpa-
tient stay or ambulatory visit with a primary diagnosis of
nephrolithiaisis were matched to the individual’s absence
data. Absences associated with a hospitalization included
work loss reported between the admission and discharge
dates, including days contiguous to those dates. For exam-
ple, if a person was admitted to the hospital on June 1 with
a primary diagnosis of nephrolithiaisis and discharged on
June 5, any sick time or short-term disability in that pe-
riod, as well as on contiguous days before June 1 and after
June 5 would be counted. However, work loss reported
on June 7 would not be included if the employee did not
miss any work time on June 6. Short-term disability hours
for individuals whose start date coincided with a hospital
admission and for whom there was a return-to-work date
were included. Work absences were capped at 12 hours
if the beginning and end dates of the absence were the
same.
Work absences associated with ambulatory visits were
calculated in two ways. The first method includes ab-
sences contiguous to the date of the visit. The second,
more conservative approach, excludes absences on con-
tiguous days unless there was some work loss on the day
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Table 2. Prevalence of upper tract nephrolithiaisis a
Prevalence Number of persons Full sample
rate with nephrolithiasis persons
Total 1.12 3600 322,556
Age
18-44 0.80 1115 138,647
45-54 1.25 1311 104,549
55-64 1.48 1174 79,360
Gender
Male 1.46 2642 180,651
Female 0.68 958 141,905
aPrevalence based on a medical claim in 2000 with a primary diagnosis of
upper tract nephrolithiaisis as defined in Table 1. Source: Ingenix, 2000.
of the visit (or preceding day). For example, the first ap-
proach would count an appropriate work absence (sick
leave) on Wednesday associated with a medical visit for
nephrolithiaisis on Tuesday. The second approach would
not count Wednesday’s work loss unless there was an ab-
sence on Tuesday as well. If two outpatient visits occurred
in the span of one absence, then hours absent before the
first visit counted toward the first visit, and hours absent
after the second visit counted toward the second visit. The
hours of work lost between the visits counted toward the
closest visit. In the event of a tie, the hours were assigned
to the first visit.
We used the Stata statistical software package
(StataCorp LP, College Station, TX, USA) to conduct
above-mentioned statistical analyses.
RESULTS
The overall prevalence in the Ingenix sample of 322,556
individuals was 1.1%. Prevalence among males was ap-
proximately double that of females (1.5% vs. 0.7%) and
increased by about 85% from the youngest to the oldest
age group (Table 2).
Direct costs
Annual health care expenditures for a person with
a primary diagnosis of nephrolithiaisis were more than
double those without such a claim after adjusting for
patient demographics, comorbid conditions, and the
generosity of health benefits. Adjusted mean annual ex-
penditures were $3038 for working-age adults without a
medical claim for nephrolithiasis in 2000 versus $6532 for
similar adults with the condition (Table 3). Persons with
a primary diagnosis of nephrolithiaisis in 2000 incurred
medical expenses of $5381 (82% of total) on average and
prescription drug expenses of $1151 (18%). Comparative
estimates for similar adults without nephrolithiasis were
$2138 and $900, respectively. Differences in spending var-
ied only modestly by age, region of the country, and sex.
Females incurred slightly higher expenditures than males.
Total medical expenditures were modestly higher in the
Table 3. Estimated annual expenditures for privately insured people
aged 18 to 64 with and without a medical claim for nephrolithiaisis in
2000a
2000 annual expenditures (PPPY)
Persons without Persons with nephrolithiaisis
nephrolithiaisis (N = 3600)
(N = 318,956)
Total Total Medical Rx drugs
All $3,038 $6,532 $5,381 $1,151
Age
18-44 $2,809 $6,114 $5,086 $1,028
45-54 $3,278 $7,093 $5,777 $1,316
55-64 $3,123 $6,525 $5,375 $1,150
Gender
Male $2,808 $6,302 $5,227 $1,075
Female $3,331 $6,825 $5,578 $1,247
Region
Northeast $2,948 $6,442 $5,367 $1,075
Midwest $2,962 $6,456 $5,369 $1,087
South $3,152 $6,647 $5,402 $1,245
West $2,978 $6,472 $5,351 $1,121
aAnnual expenditures per person. The sample consists of primary beneficiaries
ages 18 to 64 with employer-provided insurance who were continuously enrolled
in a health plan in 2000. Estimated annual expenditures were derived from
multivariate models that control for age, gender, work status (active/retired),
median HH income (zip), urban/rural residence, medical and drug plan
characteristics (plan type, deductible, coinsurance/copayments), and comorbid
conditions. Source: Ingenix, 2000.
South (about $200 per person, per year), regardless of
treatment for nephrolithiasis.
Approximately 25% of individuals with a diagnosis
of nephrolithiasis had a claim for surgical treatment of
the condition (Table 4). Rates of use for ureteroscopic
lithotripsy and ESWL were considerably higher than for
PCNL and open stone surgery. Average expenditures for
specific procedures used to treat nephrolithiasis varied
from $3624 per PCNL procedure to $1425 per uretero-
scopic lithotripsy procedure (Table 4). Subjects undergo-
ing ureteroscopic lithotripsy had lower requirements for
a second procedure. The mean number of procedures per
patient undergoing ureteroscopic lithotripsy was 1.12, as
compared with 1.22 and 1.26 for ESWL and PCNL, re-
spectively (Table 4).
Indirect costs
We also examined the impact of nephrolithiasis on
work loss among 834 employees with complete absentee
data (Table 5). Overall, 30% missed work related to their
condition, with an average work loss of 19.0 hours per
year for the full entire study sample (95% CI 14.5–23.3).
Average work loss associated with an inpatient hospital-
ization for nephrolithiaisis was 47.9 hours (95% CI 30.9–
64.9) (Table 6). Similarly, average work loss associated
with an ambulatory care visits for nephrolithiasis was 5.1
hours (95% CI 4.4–5.9) (Table 7).
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Table 4. Procedure use, expenditures, and need for repeat treatment in individuals with nephrolithiasis
Rate per 100,000 Average Mean number of
individuals with expenditure procedures per person
Procedure type nephrolithiasis per procedure having the procedure
Total 24,514 (22,819-26,209) $1,947
Percutaneous nephrostolithotomy 690 (409-970) $3,624 1.26
Open stone surgery 104 (13-196) $2,916 1.00
Extracorporeal shock wave lithotripsy 12,769 (11,605-13,933) $2,295 1.22
Ureteroscopic lithotripsy 10,930 (9930-11,930) $1,425 1.12
Table 5. Average annual work loss for persons treated for upper tract nephrolithiaisis
Average work absence (hours)
Number of % Missing
Condition personsa work Inpatient Outpatient Total
Nephrolithiaisis upper tract 834 30.0% 4.4 (2.5-6.3) 14.6 (11.5-17.7) 19.0 (14.5-23.5)
aUnit of observation is an individual with an inpatient or outpatient claim for nephrolithiaisis and for whom absence data were collected. Work loss based on reported
absences contiguous to the admission and discharge dates of each hospitalization and outpatient visit. 95% confidence interval in parentheses. Source: Marketscan, 1999.
Table 6. Average work loss associated with a hospitalization or an ambulatory care visit for upper tract nephrolithiaisis
Inpatient care Outpatient care
Number of Average work Number of Average work
Condition hospitalizationsa absence (hours) outpatient visits absence (hours)
Nephrolithiaisis 77 47.9 2,373 5.1
upper tract (30.9-64.9) (4.4-5.9)
aUnit of observation is an episode of treatment. Work loss based on reported absences contiguous to the admission and discharge dates of each hospitalization and
outpatient visit. 95% confidence interval in parentheses. Source: Marketscan, 1999.
Table 7. Average work loss associated with a hospitalization or an ambulatory care visit for upper tract nephrolithiaisis
Inpatient care Outpatient care
Number of Average work Number of Average work
Condition hospitalizationsa absence (hours) outpatient visits absence (hours)
Nephrolithiaisis 77 47.9 2,373 5.1
upper tract (30.9-64.9) (4.4-5.9)
aUnit of observation is an episode of treatment. Work loss based on reported absences contiguous to the admission and discharge dates of each hospitalization and
outpatient visit. 95% confidence interval in parentheses. Source: Marketscan, 1999.
Cost-effectiveness
Our estimates of direct and indirect costs suggest that
reducing the recurrence of nephrolithiasis in known stone
formers may be cost-effective for employers. Based on
a 6-year panel of employer data, about 60% of individ-
uals with a medical claim for nephrolithiasis were first
time stone formers (based on the absence of a related
claim in the previous 5 years). Applying this estimate to
our sample of 3600 individuals treated for nepholithia-
sis in 2000 suggests that 1440 were recurrent stone for-
mers. This group would reflect the “target population”
for a disease management program. Prior evidence sug-
gests that 50% of stone formers will have a recurrence
within 5 years [8]. If we assume the rate of recurrence
is linear over this time, then 144 recurrences will be
treated in the first year alone (1440 × .5 × .2). If 75% of
these cases [10] could be prevented with proper dietary
and medical therapy, the total savings to the employer
through the reduction in direct and indirect costs would
be over $440,000 in the first year (108 cases averted; $3494
per case in direct costs; 2.375 lost work days per case).
Under these assumptions, an intervention costing $300
per person per year would pay for itself, and could gener-
ate additional cost-savings over a longer time frame given
the expected increase in known stone formers in subse-
quent years. However, costs for current medical therapies
aimed at stone prevention generally exceed $300 per per-
son per year. Further research into less expensive alter-
natives (such as fresh lemonade, which increases urinary
citrate [9]) is indicated.
DISCUSSION
We found that in a population of more than 300,000
primary beneficiaries with employer-sponsored health
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insurance, a diagnosis of nephrolithiasis resulted in an
additional $3494 in health care expenditures in 2000
compared to a similar population without nephrolithi-
asis. Given that 3600 individuals in this group were
treated for nephrolithiasis, the total costs associated with
nephrolithiasis exceeded $12.6 million in the study pop-
ulation.
Applying national estimates of the working-age popu-
lation to prevalence data in our sample suggests that more
than 1.3 million people in the labor force ages 18 to 64 re-
ceive treatment for nephrolithiasis in a given year. Given
an incremental cost of $3494 per person, total health care
spending in the United States for evaluation, hospitaliza-
tion, and treatment of nephrolithiasis is approximately
$4.5 billion annually in the employed population. In ad-
dition, we estimate that treatment of nephrolithiasis is as-
sociated with 3.1 million lost workdays per year (among
the privately insured). If each day of work costs an em-
ployer $250, a conservative estimate, the indirect costs of
nephrolithiaisis are approximately $775 million per year
[11].
In our study, ESWL and ureteroscopic lithotripsy were
strongly favored over PCNL and open stone surgery in
the treatment of subjects with nephrolithiasis. Open stone
surgery was vanishingly rare, consistent with best practice
guidelines that consider open surgery to be a treatment
of last resort [10]. PCNL is more technically challenging
than ureteroscopic lithotripsy or ESWL, and is generally
only indicated for large renal pelvis stones, which may
explain its low utilization rate. Evidence suggests that
PCNL is the preferred mode of therapy for renal pelvis
stones >1.5 cm in size or in certain lower pole stones
due to the need for frequent retreatment compared with
ESWL, and that it is underutilized compared to ESWL in
these settings [11]. However, our study showed a similar
rate of retreatment for both ESWL and PCNL, perhaps
reflecting the community-setting results of a technique
demonstrating higher efficacy in the setting of academic
clinical trials. Retreatment rates were lowest for uretero-
scopic lithotripsy, which also incurred the lowest average
payment. However, our study cannot control for critical
factors that influence retreatment rates, including stone
size, location, and composition. It also cannot control for
patient preferences in regards to modality of treatment.
Despite the increasing prevalence of nephrolithiasis in
the United States, few prior studies have examined the
economic burden of the disease. A study by Shuster and
Scheaffer surveyed a large number of patients hospital-
ized with nephrolithiasis in the Carolinas and the Rocky
Mountain region. They estimated that the national cost
of stone disease was about $315 million for white males
age 18 to 60 [12]. However, these data are more than
20 years old, and thus are primarily of historic interest
given the dramatic changes in prevention and treatment
of nephrolithiasis since that time.
More recently, Clark et al examined the economic costs
associated with evaluation and treatment of upper uri-
nary tract calculi in the United States. They estimated
the direct and indirect cost of nephrolithiaisis was $1.83
billion in 1993 dollars, with direct costs comprising more
than 90% of the total [13].
Our estimate of $5.3 billion per year is considerably
higher than Clark et al’s figure for several reasons. First,
our data are more recent (2000) and include a period
of rapid growth in medical spending. Second, the two
studies use different methods in measuring costs. Clark
et al use average charges to estimate inpatient costs and
price fees from military hospitals to compute physician
fees and outpatient costs. They also rely on expert opinion
to estimate lost work days attributable to nephrolithiaisis.
In contrast, we use actual reimbursements to estimate the
costs of each service, and we link absentee data to service
use to provide more precise estimates of the indirect costs
associated with the treatment of nephrolithiaisis.
How does the economic burden of nephrolithiasis com-
pare with other chronic conditions? The incremental
costs of nephrolithiasis exceed that of irritable bowel syn-
drome, as measured in an employed population similar
to that of this study [14]. While the incremental costs of
nephrolithiasis are comparable to other conditions such
as diabetes and asthma [15, 16], total expenditures are
much lower due to its relatively lower prevalence.
LIMITATIONS
Our study has several limitations. First, our data in-
clude a sample of large employers from all regions of
the country. However, they are not nationally represen-
tative. Our estimates may overstate the true burden of
disease if these firms provide more generous insurance
coverage or facilitate access to more expensive providers
and facilities than the national employed population. Sec-
ond, we identified individuals receiving treatment for
nephrolithiaisis based on a primary diagnosis for the con-
dition as reported in the medical claims. Claims data do
not capture the severity of illness, nor do they allow us to
ascertain with certainty whether work absences were di-
rectly related to the treatment of nephrolithiaisis. Finally,
we used multivariate models to estimate the incremen-
tal costs associated with nephrolithiasis. Although these
models included a large set of covariates and binary indi-
cators for comorbidities, there may be unmeasured fac-
tors that affect the use of medical services differentially
across groups that were omitted from our analysis.
CONCLUSION
Treatment of nephrolithiaisis places a significant bur-
den on employees and their employers. Taken together,
the direct and indirect costs of nephrolithiaisis in the
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private sector are estimated to exceed $5.3 billion in
2000. Given recent evidence of the effectiveness of sec-
ondary preventative treatment strategies among known
stone formers, disease management efforts may be cost-
effective in a working-age population.
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